Home Healthcare Pharmaceuticals Rheumatoid Arthritis Market

Rheumatoid Arthritis Market Size, Share & Trends Analysis Report By Drug Class (Disease-modifying Antirheumatic Drugs (DMARDs), Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Uric Acid Drugs), By Route of Administration (Oral, Parental), By Sales Channel (Prescription-based Drugs, Over-the-counter Drugs) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Debashree B | Format: | Report Code: SR5631DR | Pages: 110
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Rheumatoid Arthritis Market, By Drug Class 2022-2034 (USD MILLION/ Units)
    1. Disease-modifying Antirheumatic Drugs (DMARDs)
    2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    3. Corticosteroids
    4. Uric Acid Drugs
  2. Rheumatoid Arthritis Market, By Route of Administration 2022-2034 (USD MILLION/ Units)
    1. Oral
    2. Parental
  3. Rheumatoid Arthritis Market, By Sales Channel 2022-2034 (USD MILLION/ Units)
    1. Prescription-based Drugs
    2. Over-the-counter Drugs
  4. Regional Rheumatoid Arthritis Market
    1. North America
      1. North America Rheumatoid Arthritis Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
      2. North America Rheumatoid Arthritis Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parental
      3. North America Rheumatoid Arthritis Market By Sales Channel 2022-2034 (USD MILLION/ Units)
        1. Prescription-based Drugs
        2. Over-the-counter Drugs
      4. U.S.
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
        5. Oral
        6. Parental
        7. Prescription-based Drugs
        8. Over-the-counter Drugs
      5. Canada
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
        5. Oral
        6. Parental
        7. Prescription-based Drugs
        8. Over-the-counter Drugs
    2. Europe
      1. Europe Rheumatoid Arthritis Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
      2. Europe Rheumatoid Arthritis Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parental
      3. Europe Rheumatoid Arthritis Market By Sales Channel 2022-2034 (USD MILLION/ Units)
        1. Prescription-based Drugs
        2. Over-the-counter Drugs
      4. U.K.
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
        5. Oral
        6. Parental
        7. Prescription-based Drugs
        8. Over-the-counter Drugs
      5. Germany
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
        5. Oral
        6. Parental
        7. Prescription-based Drugs
        8. Over-the-counter Drugs
      6. France
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
        5. Oral
        6. Parental
        7. Prescription-based Drugs
        8. Over-the-counter Drugs
      7. Spain
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
        5. Oral
        6. Parental
        7. Prescription-based Drugs
        8. Over-the-counter Drugs
      8. Italy
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
        5. Oral
        6. Parental
        7. Prescription-based Drugs
        8. Over-the-counter Drugs
      9. Russia
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
        5. Oral
        6. Parental
        7. Prescription-based Drugs
        8. Over-the-counter Drugs
      10. Nordic
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
        5. Oral
        6. Parental
        7. Prescription-based Drugs
        8. Over-the-counter Drugs
      11. Benelux
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
        5. Oral
        6. Parental
        7. Prescription-based Drugs
        8. Over-the-counter Drugs
      12. Rest of Europe
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
        5. Oral
        6. Parental
        7. Prescription-based Drugs
        8. Over-the-counter Drugs
    3. APAC
      1. APAC Rheumatoid Arthritis Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
      2. APAC Rheumatoid Arthritis Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parental
      3. APAC Rheumatoid Arthritis Market By Sales Channel 2022-2034 (USD MILLION/ Units)
        1. Prescription-based Drugs
        2. Over-the-counter Drugs
      4. China
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
        5. Oral
        6. Parental
        7. Prescription-based Drugs
        8. Over-the-counter Drugs
      5. Korea
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
        5. Oral
        6. Parental
        7. Prescription-based Drugs
        8. Over-the-counter Drugs
      6. Japan
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
        5. Oral
        6. Parental
        7. Prescription-based Drugs
        8. Over-the-counter Drugs
      7. India
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
        5. Oral
        6. Parental
        7. Prescription-based Drugs
        8. Over-the-counter Drugs
      8. Australia
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
        5. Oral
        6. Parental
        7. Prescription-based Drugs
        8. Over-the-counter Drugs
      9. Singapore
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
        5. Oral
        6. Parental
        7. Prescription-based Drugs
        8. Over-the-counter Drugs
      10. Taiwan
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
        5. Oral
        6. Parental
        7. Prescription-based Drugs
        8. Over-the-counter Drugs
      11. South East Asia
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
        5. Oral
        6. Parental
        7. Prescription-based Drugs
        8. Over-the-counter Drugs
      12. Rest of Asia-Pacific
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
        5. Oral
        6. Parental
        7. Prescription-based Drugs
        8. Over-the-counter Drugs
    4. Middle East and Africa
      1. Middle East and Africa Rheumatoid Arthritis Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
      2. Middle East and Africa Rheumatoid Arthritis Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parental
      3. Middle East and Africa Rheumatoid Arthritis Market By Sales Channel 2022-2034 (USD MILLION/ Units)
        1. Prescription-based Drugs
        2. Over-the-counter Drugs
      4. UAE
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
        5. Oral
        6. Parental
        7. Prescription-based Drugs
        8. Over-the-counter Drugs
      5. Turkey
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
        5. Oral
        6. Parental
        7. Prescription-based Drugs
        8. Over-the-counter Drugs
      6. Saudi Arabia
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
        5. Oral
        6. Parental
        7. Prescription-based Drugs
        8. Over-the-counter Drugs
      7. South Africa
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
        5. Oral
        6. Parental
        7. Prescription-based Drugs
        8. Over-the-counter Drugs
      8. Egypt
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
        5. Oral
        6. Parental
        7. Prescription-based Drugs
        8. Over-the-counter Drugs
      9. Nigeria
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
        5. Oral
        6. Parental
        7. Prescription-based Drugs
        8. Over-the-counter Drugs
      10. Rest of MEA
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
        5. Oral
        6. Parental
        7. Prescription-based Drugs
        8. Over-the-counter Drugs
    5. LATAM
      1. LATAM Rheumatoid Arthritis Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
      2. LATAM Rheumatoid Arthritis Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parental
      3. LATAM Rheumatoid Arthritis Market By Sales Channel 2022-2034 (USD MILLION/ Units)
        1. Prescription-based Drugs
        2. Over-the-counter Drugs
      4. Brazil
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
        5. Oral
        6. Parental
        7. Prescription-based Drugs
        8. Over-the-counter Drugs
      5. Mexico
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
        5. Oral
        6. Parental
        7. Prescription-based Drugs
        8. Over-the-counter Drugs
      6. Argentina
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
        5. Oral
        6. Parental
        7. Prescription-based Drugs
        8. Over-the-counter Drugs
      7. Chile
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
        5. Oral
        6. Parental
        7. Prescription-based Drugs
        8. Over-the-counter Drugs
      8. Colombia
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
        5. Oral
        6. Parental
        7. Prescription-based Drugs
        8. Over-the-counter Drugs
      9. Rest of LATAM
        1. Disease-modifying Antirheumatic Drugs (DMARDs)
        2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        3. Corticosteroids
        4. Uric Acid Drugs
        5. Oral
        6. Parental
        7. Prescription-based Drugs
        8. Over-the-counter Drugs
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.